Receive our newsletter – data, insights and analysis delivered to you
  1. News
November 17, 2020

Qiagen unveils multiplex test for SARS-CoV-2 in Europe

Netherlands-based Qiagen has launched NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test in Europe to identify and differentiate between common seasonal respiratory infections and Covid-19.

Netherlands-based Qiagen has launched NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Test in Europe to identify and differentiate between common seasonal respiratory infections and Covid-19.

The easy-to-use multiplex polymerase chain reaction (PCR) test detects and differentiates influenzas A and B, respiratory syncytial virus (RSV), and SARS-CoV-2 infections in 80 minutes. 

Since these viruses produce similar respiratory symptoms, it is crucial to provide differential diagnosis among them for treating patients and for management decisions.

The launch of NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test in the EU and other markets comes after it obtained CE-IVD registration.

Qiagen has submitted an application to the Food and Drug Administration (FDA) for obtaining emergency use authorisation (EUA) for the test.

The respiratory test uses NeuMoDx 96 and NeuMoDx 288 molecular systems’ automated three-step workflow. 

Content from our partners
Precision wire: The future of bespoke medical treatment
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
“This technique means everything to us”: How CGM devices empower users 

It also features processing capacity, true random access, and continuous loading of samples, reagents, and consumables while the system is running.

Furthermore, the company has expanded specimen types that can be used on the existing NeuMoDx SARS-CoV-2 test. 

Qiagen obtained CE-IVD approval for the use of saliva samples collected with the NeuMoDx Saliva Collection Kit.

The kit has a collection vial, stabilisation tube and pipette. It helps to perform less invasive sample collection compared to commonly used nasal swabs. 

Qiagen CEO Thierry Bernard said: “Both launch and label extension expand the capabilities of our NeuMoDx systems in detection of Covid-19. 

“They add to our growing NeuMoDx testing menu, which in 2020, included launches for HIV-1, TV/MG, Strep A/C/G, HPV, BK virus, and Influenza A-B/RSV.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU